Literature DB >> 6849223

The effects of nifedipine, a calcium antagonist, on platelet function.

J Dale, K H Landmark, E Myhre.   

Abstract

Platelet function was studied before and 1 hour after ingestion of 20 mg nifedipine, a new calcium antagonist, in 20 patients with coronary heart disease. Platelet counts remained unchanged. Platelet adhesiveness, measured as retention in glass bead columns with Hellem's method for native blood, did not drop significantly eigher when 0.9 or 3.6 ml of blood was used. Platelet aggregation, which is dependent on extracellular calcium, was induced in citrated platelet-rich plasma. The mean maximal rate of primary aggregation, initiated with three different concentrations of adenosine diphosphate, was reduced by 20% to 26%. The rate of irreversible collagen-induced aggregation was on average 23% lower after nifedipine. The mean bleeding time was 36 seconds, or 12%, longer after ingestion of the drug. The moderate, but significant reduction of platelet aggregation and prolongation of the bleeding time by nifedipine may be mediated through inhibition of calcium transport across the platelet membrane.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849223     DOI: 10.1016/0002-8703(83)90285-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  23 in total

Review 1.  Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy.

Authors:  P M Kyle; C W Redman
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

2.  Effect of nifedipine monotherapy on platelet aggregation in patients with untreated essential hypertension.

Authors:  Z Ośmiałowska; M Nartowicz-Słoniewska; J M Słomiński; B Krupa-Wojciechowska
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Effects of the calmodulin antagonists fendiline and calmidazolium on aggregation, secretion of ATP, and internal calcium in washed human platelets.

Authors:  A Lückhoff; M Bohnert; R Busse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-01       Impact factor: 3.000

Review 4.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

5.  The effects of intravenous and oral nifedipine on ex vivo platelet function.

Authors:  T J Walley; K L Woods; D B Barnett
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Antiplatelet effects of oral diltiazem, propranolol, and their combination.

Authors:  M E Ring; J J Corrigan; P E Fenster
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

7.  The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.

Authors:  J L Francis; O S Roath; V F Challenor; D G Waller
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

8.  The effects of nifedipine on platelet aggregation and plasma 6-keto-PGF1 alpha, and its interaction with indomethacin.

Authors:  M B Murphy; M A Orchard; E L Conway; S E Barrow
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Clinical and laboratory effects of nifedipine in Raynaud's phenomenon.

Authors:  S J Hawkins; C M Black; N D Hall; A McGregor; E F Ring; P J Maddison
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

10.  Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy.

Authors:  M R Lawrence; F Broughton Pipkin
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.